SAN FRANCISCO (GenomeWeb News) – Genomic Health will launch its colon cancer test this quarter and will hire additional sales people in connection with the introduction, President and CEO Kim Popovits said Monday at the JP Morgan Healthcare Conference, held here this week.

The pharmacogenomics firm currently has 80 sales people and expects to add another 10 this quarter. Popovits said that its entire sales force would sell both the Oncotype Dx for breast cancer and the new assay for colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.